Abstract:

Objective  To evaluate the clinical characteristics in female patients with coronary heart disease after percutaneous coronary intervention (PCI) and the protective influence of β-adrenergic blocker therapy on patients before PCI. Methods  We recruited 266 consecutive subjects with coronary heart disease (191 males, 75 females) treated withβ-adrenergic blocker before and after PCI. 50 consecutive subjects with coronary heart disease were also involved, but  they did not received βadrenergic blocker therapy. Data were examined for gender-specific differences regarding patients' characteristics, angiographic findings, procedural details and adverse events at 1 year after PCI. Also, a blood sample was collected from each subject to determine the levels of creatine kinase-MB, TNT, E and NE. Results   Compared with  male subjects, multi-vessel lesions were significantly higher in  female subjects. Also, women had significantly higher prevalence of cumulative vascular complications, renal failure and unadjusted mortality. E, NE, CKMB and TNT levels significantly increased before and after PCI in the female coronary heart disease subjects withoutβadrenergic blocker therapy compared with those treated with β-adrenergic blocker. Overall, female subjects withoutβadrenergic blocker therapy were more likely to have in-hospital major adverse cardiac events(MACE), recurrent angina, cardiac arrhythmias and vascular complications. Conclusion  Women who undergo PCI therapy for coronary heart disease often have severer coronary artery lesions and higher post-PCI complication and mortality rates. Oral administration of β-adrenergic blocker has a protective effect on female patients before PCI.

Key words: Coronary arteriosclerosis；Female; β  adrenergic blocker；  Percutaneous coronary intervention